Objective: Retrospective studies have indicated that anti-thyroid drugs (ATD) might possess a radioprotective effect, leading to a higher rate of recurrence of hyperthyroidism after iodine-131 ( 131 I) therapy. Design: A randomized clinical trial was performed to clarify whether resumption of methimazole after 131 I influences the final outcome of this treatment. Methods: We assigned 149 patients with Graves' disease or a toxic nodular goitre to groups either to resume (þATD) or not to resume (2ATD) methimazole 7 days after 131 I. Before
131I therapy, all patients were rendered euthyroid by methimazole, which was discontinued 4 days before the 131 I therapy. Results: During the follow-up period of 12 months, 13 patients developed hypothyroidism, 42 were euthyroid, and 18 had recurrence of hyperthyroidism in the þATD group; the respective numbers in the 2ATD group were 16, 42 and 18 (P ¼ 0.88). At 3 weeks after 131 I therapy, the serum free-thyroxine index was slightly decreased (by 5.7%; 95% confidence interval (CI) 215.5 to 5.4%) in the þ ATD group, in contrast to an increase of 35.9% (95% CI 18.8 to 55.5%) in the 2ATD group (P , 0.001 between groups). In the subgroup that remained euthyroid during follow-up, thyroid volume reduction, assessed by ultrasonography, was smaller in the þATD group [38.7% (95% CI 33.3to 44.1%)] than in the 2ATD group [48.6% (95% CI: 41.5 -55.6%)] (P , 0.05).
Conclusion:No radioprotective effect could be demonstrated, with regard to final thyroid function, for the resumpton of methimazole 7 days after 131 I therapy. Although resumption of methimazole slightly reduced the magnitude of shrinkage of the goitre obtained by 131 I, the prevention of a temporary thyrotoxicosis in the early period after radiation favours this regimen.